328.F MEIRAGTX HLDGSDL-0000388
- Market cap
- EUR 831M
- P/E
- 11.5x
- P/B
- 4.27x
- ROE
- 106.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 328.F undervalued?
Graham number328.F trades 48.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MEIRAGTX HLDGSDL-0000388 fundamental analysis
No fundamental analysis for MEIRAGTX HLDGSDL-0000388 yet.
MEIRAGTX HLDGSDL-0000388 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MEIRAGTX HLDGSDL-0000388
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkin…
Full company profileMEIRAGTX HLDGSDL-0000388 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MEIRAGTX HLDGSDL-0000388 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 37.7M | 15.9M | 14.0M | 33.3M | 81.4M | 643M |
| Gross Profit | - | - | 14.0M | 9.49M | 76.5M | 629M |
| Operating Income | -72.8M | -116M | -137M | -164M | -106M | 407M |
| EBITDA | - | -116M | -57.1M | -122M | -89.4M | 258M |
| Net Income | -79.6M | -130M | -84.0M | -148M | -114M | 229M |
| EPS | -1.79 | -2.67 | -1.32 | -1.89 | -1.41 | 2.43 |
| Balance Sheet | ||||||
| Total Assets | 320M | 318M | 327M | 270M | 244M | 396M |
| Total Liabilities | 135M | 200M | 189M | 202M | 250M | 181M |
| Shareholders' Equity | 185M | 118M | 138M | 67.8M | -5.79M | 216M |
| Cash & Short-term Investments | 138M | 116M | 130M | 104M | 65.9M | 143M |
| Cash Flow | ||||||
| Operating Cash Flow | -10.5M | -73.1M | -105M | -104M | -46.4M | -41.5M |
| Capital Expenditure | 55.2M | 45.0M | 20.2M | 4.96M | 4.24M | 53.1M |
| Free Cash Flow | -65.7M | -118M | -126M | -109M | -50.6M | -94.6M |
| Ratios | ||||||
| ROE | -42.9% | -110.1% | -60.8% | -217.9% | - | 106.1% |
| ROA | -24.9% | -40.7% | -25.7% | -54.8% | -46.7% | 57.7% |
| Net Profit Margin | -211.0% | -814.2% | -599.5% | -444.1% | -140.3% | 35.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MEIRAGTX HLDGSDL-0000388 dividends
MEIRAGTX HLDGSDL-0000388 has not paid dividends in the last 5 fiscal years.
Who owns MEIRAGTX HLDGSDL-0000388
- Insiders 16.27%
- Institutions 73.56%
- Public & others 10.17%
- Shares outstanding 96.0M
- Free float 53.8M
MEIRAGTX HLDGSDL-0000388 company profile
- Company name
- MEIRAGTX HLDGSDL-0000388
- Ticker
- 328.F
- ISIN
- KYG596651029
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 393
- Fiscal year end
- December
- Address
- 655 Third Avenue, New York, NY, United States, 10017
- Phone
- 646 860 7985
- Website
- meiragtx.com
About MEIRAGTX HLDGSDL-0000388
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
MEIRAGTX HLDGSDL-0000388 management
10- Dr. Alexandria Forbes Ph.D.CEO, President & Director · born 1965
- Mr. Richard Brian Giroux B.A.COO & CFO · born 1974
- Dr. Robert K. Zeldin M.D.Chief Medical Officer · born 1963
- Mr. Robert J. Wollin J.D.General Counsel & Secretary · born 1976
- Dr. Stuart Naylor Ph.D.Chief Scientific Officer of Ophthalmology · born 1963
- Dr. Michel Michaelides F.A.C.S., M.D., MBBSHead of Clinical Ophthalmology
- Ms. Christine Elise SheehySenior Vice President of Global Integration · born 1968
- Mr. Tim RandallSenior Vice President of Risk & Internal Controls
- Dr. David Rubinstein Ph.D.Senior Vice President of Business Development
- Dr. Tassos Georgiadis Ph.D.Senior Vice President of Discovery & Preclinical Development